Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].

Altawalbeh, Shoroq M; Wateska, Angela R; Patricia Nowalk, Mary; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J

Altawalbeh, Shoroq M; Wateska, Angela R; Patricia Nowalk, Mary; Lin, Chyongchiou J; Harrison, Lee H; Schaffner, William; Zimmerman, Richard K; Smith, Kenneth J.

Afiliação

Altawalbeh SM; Jordan University of Science and Technology, Faculty of Pharmacy, Irbid, Jordan.
Wateska AR; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Patricia Nowalk M; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; The Ohio State University College of Nursing, Columbus, OH, United States.
Lin CJ; The Ohio State University College of Nursing, Columbus, OH, United States.
Harrison LH; Center for Genomic Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Schaffner W; Vanderbilt University School of Medicine, Nashville, TN, United States.
Zimmerman RK; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Smith KJ; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Vaccine ; 2024 Jul 15.

Article em En | MEDLINE | ID: mdl-39013693

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccine Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Jordânia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google